PRESENTATION · Sep 2025 · PDF
Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
PRESENTATION · Sep 2025 · PDF
Acoramidis-HFSA-2025-Effect-on-CVM_Recurrent-CVH-Cumulative-Incidence-Oral-Presentation
PRESENTATION · Sep 2025 · PDF
Acoramidis-HFSA-2025-NT-proBNP-in-ATTRv-CM
PRESENTATION · Sep 2025 · PDF
Acoramidis-HFSA-2025-OLE-ACM-and-CVH-by-Genotype
PRESENTATION · Sep 2025 · PDF
Acoramidis-HFSA-2025-Cardiac-Conduction-abnormalities
PRESENTATION · Sep 2025 · PDF
Encaleret - Chronic Hypoparathyroidism - Proof of Concept Study in Post-Surgical Hypoparathyroidism
PRESENTATION · Sep 2025 · PDF
Infigratinib - Crouzon/Pfeiffer Syndromes - Preclinical Improvement in Skull Measures
PRESENTATION · Sep 2025 · PDF
Infigratinib - Hypochondroplasia - Preclinical Improvement in Bone Growth
PRESENTATION · Aug 2025 · PDF
BBIO - Acoramidis TTR- ESC 2025 - Improvement in NT-proBNP
PRESENTATION · Aug 2025 · PDF